- Home
- NUWE vs BDRX Comparison
NUWE vs BDRX Comparison
Compare NUWE & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUWE | BDRX |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United Kingdom |
| Employees | 38 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.8M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NUWE | BDRX |
|---|---|---|
| Price | $1.66 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 174.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.79 |
| 52 Week High | $25.95 | $11.88 |
Technical Indicators
Market Signals| Indicator | NUWE | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.20 | 32.74 |
| Support Level | $0.20 | $1.03 |
| Resistance Level | $2.09 | $1.29 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 2.04 | 20.65 |
Price Performance
Historical ComparisonAbout NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.